Table 2. SIRs of second primary cancers in survivors of multiple myeloma (MM) in Germany and Sweden for overall and by study period*.
| Sites of second cancers | Germany |
Sweden |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1997–2003 |
2004–2010 |
Overall |
1997–2003 |
2004–2010 |
Overall |
|||||||||||||
| N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | N | SIR | 95%CI | |
| Stomach | 9 | 1.2 | (0.5–2.2) | 21 | 1.3 | (0.8–2.0) | 41 | 1.1 | (0.8–1.5) | 5 | 1.3 | (0.4–3.1) | 2 | 0.9 | (0.1–3.3) | 8 | 1.4 | (0.6–2.7) |
| Colorectum | 35 | 1.3 | (0.9–1.8) | 33 | 0.5 | (0.4–0.7) | 104 | 0.7 | (0.6–0.9) | 20 | 1.0 | (0.6–1.5) | 22 | 1.1 | (0.7–1.7) | 57 | 1.3 | (1.0–1.7) |
| Liver and gallbladder | 4 | 0.9 | (0.2–2.3) | 15 | 1.4 | (0.8–2.3) | 23 | 1.0 | (0.6–1.4) | 3 | 1.4 | (0.3–4.0) | 1 | 2.8 | (0.1–16) | 6 | 1.5 | (0.5–3.2) |
| Lung | 18 | 0.9 | (0.5–1.4) | 41 | 0.9 | (0.6–1.2) | 84 | 0.8 | (0.6–1.0) | 9 | 1.0 | (0.5–1.9) | 6 | 1.6 | (0.6–3.6) | 22 | 1.3 | (0.8–2.0) |
| Breast | 13 | 0.6 | (0.3–1.1) | 34 | 0.7 | (0.5–1.0) | 69 | 0.7 | (0.6–0.9) | 11 | 0.9 | (0.5–1.7) | 9 | 1.0 | (0.5–1.9) | 30 | 1.1 | (0.8–1.6) |
| Endometrium | 4 | 1.0 | (0.3–2.6) | 3 | 0.4 | (0.1–1.0) | 8 | 0.4 | (0.2–0.8) | 2 | 1.0 | (0.1–3.5) | 0 | 0.0 | 5 | 1.0 | (0.3–2.4) | |
| Prostate | 27 | 1.1 | (0.7–1.6) | 62 | 0.8 | (0.6–1.0) | 117 | 0.7 | (0.6–0.9) | 16 | 0.7 | (0.4–1.2) | 27 | 1.6 | (1.1–2.4) | 65 | 1.2 | (0.9–1.6) |
| Kidney | 10 | 1.6 | (0.8–2.9) | 16 | 1.1 | (0.6–1.8) | 35 | 1.1 | (0.7–1.5) | 8 | 2.9 | (1.3–5.8) | 7 | 1.8 | (0.7–3.8) | 17 | 2.3 | (1.3–3.7) |
| Urinary bladder | 6 | 0.7 | (0.3–1.5) | 9 | 0.5 | (0.2–0.9) | 23 | 0.5 | (0.3–0.8) | 3 | 0.7 | (0.1–2.0) | 10 | 1.5 | (0.7–2.8) | 19 | 1.0 | (0.6–1.5) |
| Melanoma | 8 | 2.2 | (1.0–4.4) | 12 | 0.7 | (0.3–1.2) | 31 | 1.3 | (0.9–1.9) | 6 | 1.3 | (0.5–2.8) | 9 | 1.3 | (0.6–2.5) | 22 | 1.4 | (0.9–2.1) |
| Nervous system | 4 | 2.3 | (0.6–5.9) | 5 | 1.2 | (0.4–2.7) | 12 | 1.3 | (0.6–2.2) | 9 | 2.0 | (0.9–3.9) | 5 | 1.2 | (0.4–2.7) | 17 | 1.9 | (1.1–3.1) |
| Non–Hodgkin lymphoma | 5 | 1.1 | (0.3–2.5) | 11 | 0.9 | (0.4–1.6) | 22 | 0.8 | (0.5–1.3) | 6 | 1.4 | (0.5–3.1) | 4 | 1.7 | (0.5–4.3) | 16 | 1.5 | (0.9–2.5) |
| Leukemia | 12 | 3.2 | (1.6–5.6) | 12 | 1.3 | (0.7–2.3) | 35 | 1.7 | (1.2–2.4) | 8 | 1.7 | (0.7–3.4) | 9 | 1.9 | (0.9–3.5) | 24 | 1.6 | (1.0–2.4) |
| Myeloid leukemia | 11 | 7.7 | (3.8–14) | 10 | 2.6 | (1.3–4.9) | 31 | 3.8 | (2.6–5.4) | 6 | 3.0 | (1.1–6.5) | 3 | 1.7 | (0.3–4.8) | 14 | 2.0 | (1.1–3.3) |
| Acute myeloid leukemia | 8 | 9.7 | (4.2–19) | 8 | 3.5 | (1.5–6.9) | 24 | 4.9 | (3.2–7.3) | 6 | 3.8 | (1.4–8.3) | 2 | 2.2 | (0.3–7.8) | 13 | 2.3 | (1.2–4.0) |
| Chronic myeloid leukemia | 1 | 2.3 | (0.1–13) | 0 | 1 | 0.5 | (0.0–2.6) | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |||||
| Unknown primary | 2 | 0.6 | (0.1–2.1) | 11 | 1.4 | (0.7–2.4) | 16 | 0.9 | (0.5–1.4) | 6 | 1.0 | (0.4–2.3) | 2 | 1.6 | (0.2–5.9) | 10 | 1.5 | (0.7–2.8) |
| Total combineda | 193 | 1.2 | (1.1–1.4) | 350 | 0.9 | (0.8–1.0) | 752 | 0.9 | (0.8–0.9) | 124 | 1.0 | (0.9–1.2) | 124 | 1.3 | (1.1–1.6) | 349 | 1.3 | (1.2–1.4) |
Only cancers with at least 5 SPC cases (except interested subtypes of leukemia) are presented.
*Rounding off for SIRs above 10; Bold type (elevated risk) and underscored type (decreased risk): 95% CIs did not include 1.00.
aIncluding cancers not presented individually.